4th How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten

4th How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
Our Chairs
Information
SAVE THE DATE:
September 24-26, 2027 - Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
#ESHCART2027
ABOUT THE CONFERENCE:
The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed.
The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, including a maximum level of interaction between faculty and registered participants.
In addition to the scientific and medical issues addressed during the conference, the questions of affordability and access to these novel expensive treatments will be tackled.
MAIN SCIENTIFIC TOPICS:
• Non-hodgkin lymphoma
• Multiple myeloma
• The future of CAR-T: in vivo or allo CAR-T?
• In vivo gene transfer
• Novel indications of CAR-T cell therapy
• Global access issues in CAR-T and treatment with bispecific antibodies
• CAR-T in multiple myeloma: first line or later lines?
• Long term survivorship after CAR-T and bispecifics
• Trials in progress in CAR-T
• How to optimize patients for response and toxicity after CAR-T and bispecifics treatments
LEARNING OBJECTIVES:
• Understanding of the current landscape of bispecific antibodies in NHL and MM
• Understanding of the current landscape of CAR-T cell therapy in NHL and MM
• Novel approaches and technologies in the field
• Integration of novel therapies into current clinical practice
• Understanding the management of side effects of CAR T-cell therapy and bispecific antibodies
• Understand potential indications and sequencing of CAR-T cells and bispecifics
THE PROGRAMME WILL INCLUDE:
• Keynote lectures
• Case-based lectures
• Interactive Case Presentations
• Roundtables
• Panel Discussions
• Debates
• Poster Walks
• Meet the Expert Sessions
• Voting technology
• Brief Oral Communications
• Ample time for in-depth discussions and networking
This conference is a Face to Face meeting. No virtual attendance is scheduled.
Programme
Read the final programme!
Registration
REGISTRATION IS OPEN!
The registration fee for the ESH 4th How I Manage: CAR-T Therapies and Bispecific Antibodies for my Patients is:
• 600€ for fully trained
• 300€ for in-training *
• 300€ Allied Health Professionals
• 600€ for Corporate
*A proof will be requested to confirm your status.
ESH is pleased to offer BHS, BSH, DGHO, HSH, OeGHO, PTHiT, SEHH, SFH (French), SFH (Swedish) & SPH Members a 20% discount on the conference registration fees.
This fee includes:
• Your seat in the Conference Room
• The conference materials,
• Welcome cocktail, luncheons, refreshments throughout the conference.
Your seat in the conference will be definitively reserved upon receipt of your fee.
Cancellation policy of registration fee:
In case of cancellation, up until two months prior to the beginning of the meeting, your registration fee will be reimbursed in full (less bank charges). If the cancellation is notified between 60 to 15 days prior to the beginning of the meeting, 50% of the registration fee will be reimbursed (less bank charges). Cancellations notified 15 days before the meeting will not be reimbursed. For credit card payments please register on-line first. Please note that ESH can accept VISA and MASTERCARD/EUROCARD.
Abstract submission
Call for abstracts and Clinical Cases!
Clinical cases and abstracts are eligible to be selected for a brief oral communication or a poster presentation.
Deadline for submission: June 30, 2027 (23:59 CEST)
Clinical Case Presentation Guidelines:
1. Clinical cases must be relevant to the topic of the meeting.
2. Maximum number of words: 500
3. Your clinical case will be submitted to peer review.
Abstract Guidelines:
1. Your abstract can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured.
2. Maximum number of words: 500
3. Your abstract will be submitted to peer review.
We accept “encore” abstract.
Presentation of data at this conference will not jeopardize acceptance of the same at the following ASH congress.
Venue
Clarion Hotel, Stockholm
Ringvägen 98, 118 60 Stockholm, Sweden
Accommodation
Clarion Hotel, Stockholm
Ringvägen 98, 118 60 Stockholm, Sweden
Warning!
We have detected scam activity of a company trying to sell accommodation services to the speakers of our conferences. Apparently, they have been collecting information on the speakers from the lists that are made public on our websites.
Please make sure you book your accommodation either via the link(s) provided by ESH on this page, or directly with the hotel or renown booking services platform.


.jpg)